A5048039851- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Kruppel-like factors research
- Eosinophilic Disorders and Syndromes
- Acute Myeloid Leukemia Research
- Hemoglobinopathies and Related Disorders
- Systemic Lupus Erythematosus Research
- Bone and Joint Diseases
- Cytokine Signaling Pathways and Interactions
- Autoimmune and Inflammatory Disorders Research
- Long-Term Effects of COVID-19
- COVID-19 Clinical Research Studies
- Iron Metabolism and Disorders
- Inflammasome and immune disorders
- Multiple Myeloma Research and Treatments
- Rheumatoid Arthritis Research and Therapies
- Trace Elements in Health
Azienda Ospedaliero-Universitaria Careggi
2022-2024
University of Florence
2020-2024
Abstract We describe 1000 patients with essential thrombocythemia seen at the Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Florence, Italy, between 1980 2023: median age 59 years (18–95), females 65%, JAK2 / CALR MPL -mutated 66%/19%/4%, triple-negative (TN) 11%. Extreme thrombocytosis (ExT, platelets ≥1000 × 10 9 /L) in 16%, leukocytosis (leukocytes >11 least one cardiovascular risk factor 52% cases. were older (median 62 years) TN (53 for both) younger ( p...
Abstract Overwhelming inflammatory reactions contribute to respiratory distress in patients with COVID-19. Ruxolitinib is a JAK1/JAK2 inhibitor potent anti-inflammatory properties. We report on prospective, observational study 34 COVID-19 who received ruxolitinib compassionate-use protocol. Patients had severe pulmonary disease defined by infiltrates imaging and an oxygen saturation ≤ 93% air and/or PaO2/FiO2 ratio 300 mmHg. Median age was 80.5 years, 85.3% ≥ 2 comorbidities. exposure time...
Abstract Among 281 patients with essential thrombocythemia and calreticulin (CALR) mutation, we found a variant allele frequency of ≥60% to be associated significantly shortened myelofibrosis-free survival, mostly apparent CALR type-1 type-indeterminate mutations.